Navigation Links
Anesiva Receives NASDAQ Delisting Staff Determination Letter
Date:7/23/2009

SOUTH SAN FRANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) received, as previously disclosed on its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 2, 2009 and in its press release on April 1, 2009, a letter from the NASDAQ Stock Market LLC ("NASDAQ") on March 27, 2009, informing Anesiva that it was not in compliance with Marketplace Rule 4450(a)(3) (which has since been superseded by Rule 5450(b)(1)(A)) (the "Rule"), because Anesiva's stockholder's equity at December 31, 2008 was less than the minimum $10.0 million required for continued listing on The NASDAQ Global Market.

On July 17, 2009, Anesiva received a letter from NASDAQ notifying Anesiva that based on NASDAQ's further review of Anesiva and material submitted by Anesiva, Anesiva has failed to regain compliance with the Rule and that, therefore, NASDAQ has determined to delist the Company's securities from The NASDAQ Global Market.

Anesiva has requested a hearing before a NASDAQ Hearings Panel to appeal the determination to delist Anesiva's securities. Anesiva's securities will remain listed on The NASDAQ Global Market pending a decision by the Hearings Panel following the hearing.

About Anesiva

Anesiva seeks to be a leader in the development and commercialization of novel pharmaceutical products for pain management. The company's lead product candidate is Adlea, a novel small molecule formulation of capsaicin that is currently in development for the management of acute pain following orthopedic surgeries. Adlea has been shown in clinical trials to provide extended pain relief after only a single administration in multiple indications for site-specific, acute and chronic, moderate-to-severe pain.

In December 2008, Anesiva announced that a Phase 3 clinical trial of Adlea achieved its primary efficacy endpoint of reduced post-surgical pain versus placebo (p=0.03) following total knee arthroplasty (TKA) at four to 48 hours after surgery. The trial also met its key secondary endpoint with Adlea demonstrating a highly significant reduction in opioid medication consumption compared to placebo (p=0.005).

The Phase 3 TKA trial, known as ACTIVE-2, also showed that Adlea's safety profile of adverse events, wound healing, and wound sensory function were similar to placebo over the study duration.

Forward-Looking Statements

Except for historical information, this press release may be deemed to contain "forward-looking" statements. Words such as "seek," "may," "will," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include the continued listing of Anesiva's common stock on The NASDAQ Global Market and matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the risk that Anesiva otherwise fails to comply with the continued listing requirements of The NASDAQ Global Market or any other NASDAQ market as well as other risks detailed from time to time in Anesiva's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009. Anesiva expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Anesiva, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
2. Anesiva Announces Conference Call and Webcast to Discuss Updates to Corporate Strategy and Milestones
3. Anesiva Announces Appointment of William Houghton, M.D. as Senior Vice President and Chief Medical Officer
4. Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
7. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
8. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
9. Anesiva Announces First Quarter 2008 Financial Results
10. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
11. Anesiva Announces Expansion of Zingo Agreement in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... 2016 The global ... reach USD 1.83 billion by 2024, according to ... Technological proliferation and increasing demand in commercial buildings, ... drive the market growth.      (Logo: ... development of advanced multimodal techniques for biometric authentication ...
(Date:6/9/2016)... control systems is proud to announce the introduction of fingerprint attendance control software, allowing ... are actually signing in, and to even control the opening of doors. ... ... ... Photo - http://photos.prnewswire.com/prnh/20160609/377487 ...
Breaking Biology News(10 mins):